Zafirlukast

Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), that is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. It is grouped under the following drug class(es): Leukotriene modifiers. Its therapeutic use is listed as anti-asthmatic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Vanticon, Zafirst and Respix. Its PubChem CID is 5717.

CAS No 107753-78-6
Molecular Formula C31H33N3O6S
Molecular Weight 575.70 g/mol
Synonyms cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate

Frequently Asked Questions